RxDoctor Payments Data

Dhruti Desai

Hospice and Palliative Medicine · Coppell, TXNPI 1043602238

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Dexcom, Inc. at 46.7% of the total. Reporting peaked in 2021 at $188 and has fallen 82.9% since, to $32 in 2023.

$265in general payments, 2019–2025

Across 10 payments — averaging $26.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$124
  • AbbVie$30
  • Dynavax Technologies Corporation$20
  • Astellas Pharma US Inc$19
  • Merck$18
  • Biohaven Pharmaceuticals, Inc.$16
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$265 in reported general payments places this provider in the 70th percentile of 136 hospice and palliative medicine providers in Texas.

See all hospice and palliative medicine providers in Texas

Medicare billing

Part B allowed, 2024
$21,666
Medicare patients
150
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$19,780
Albuterol Sulfate HfaAlbuterol Sulfate24$825
Atorvastatin Calcium79$505
Rosuvastatin Calcium25$467
Etodolac22$456
Pantoprazole Sodium30$339
Levothyroxine Sodium51$336
Fluoxetine Hcl12$285
Metformin Hcl31$280
Gabapentin25$277
Montelukast Sodium26$277
Omeprazole12$245
Losartan Potassium34$218
Potassium Chloride11$190
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$12$19,78020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 136 hospice and palliative medicine providers in Texas.

Other hospice and palliative medicine in Coppell

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →